Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

979 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Sanchorawala V, Wechalekar AD, Kim K, Schönland SO, Landau HJ, Kwok F, Suzuki K, Dispenzieri A, Merlini G, Comenzo RL, Cherepanov D, Hayden VC, Kumar A, Labotka R, Faller DV, Kastritis E. Sanchorawala V, et al. Among authors: dispenzieri a. Am J Hematol. 2023 May;98(5):720-729. doi: 10.1002/ajh.26866. Epub 2023 Feb 14. Am J Hematol. 2023. PMID: 36708469 Free article. Clinical Trial.
Amyloidosis.
Gertz MA, Lacy MQ, Dispenzieri A. Gertz MA, et al. Among authors: dispenzieri a. Hematol Oncol Clin North Am. 1999 Dec;13(6):1211-33, ix. doi: 10.1016/s0889-8588(05)70122-2. Hematol Oncol Clin North Am. 1999. PMID: 10626146 Review.
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Comenzo RL, et al. Among authors: dispenzieri a. Leukemia. 2012 Nov;26(11):2317-25. doi: 10.1038/leu.2012.100. Epub 2012 Apr 5. Leukemia. 2012. PMID: 22475872 Review.
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.
Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL. Merlini G, et al. Among authors: dispenzieri a. Leukemia. 2016 Oct;30(10):1979-1986. doi: 10.1038/leu.2016.191. Epub 2016 Jul 15. Leukemia. 2016. PMID: 27416985 Free PMC article. Review.
Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.
Sidana S, Sidiqi MH, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Leung N, Warsame R, Kourelis TV, Wolf RC, Hogan WJ, Kumar SK, Gertz MA. Sidana S, et al. Among authors: dispenzieri a. Am J Hematol. 2019 Sep;94(9):1020-1026. doi: 10.1002/ajh.25566. Epub 2019 Jul 11. Am J Hematol. 2019. PMID: 31254301 Free article. Clinical Trial.
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
Sidana S, Muchtar E, Sidiqi MH, Jevremovic D, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, Kyle RA, Gertz MA, Kumar SK. Sidana S, et al. Among authors: dispenzieri a. Am J Hematol. 2020 May;95(5):497-502. doi: 10.1002/ajh.25746. Epub 2020 Feb 14. Am J Hematol. 2020. PMID: 32010993 Free PMC article.
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma.
Cook J, Johnson I, Higgins A, Sidana S, Warsame R, Gonsalves W, Gertz MA, Buadi F, Lacy M, Kapoor P, Dispenzieri A, Kourelis T, Dingli D, Fonder A, Hayman S, Hobbs M, Hwa YL, Kyle R, Leung N, Go R, Rajkumar VS, Kumar S. Cook J, et al. Among authors: dispenzieri a. Am J Hematol. 2021 Mar 1;96(3):330-337. doi: 10.1002/ajh.26074. Epub 2021 Jan 13. Am J Hematol. 2021. PMID: 33326116 Free article.
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort.
Drosou ME, Vaughan LE, Muchtar E, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kapoor P, Kourelis T, Kumar S, Kyle RA, Lacy MQ, Lin Y, Lopez CL, Lust JA, Rajkumar SV, Russell SJ, Sidana S, Siddiqui MA, Sidiqi MH, Warsame R, Leung N. Drosou ME, et al. Among authors: dispenzieri a. Am J Hematol. 2021 Apr 1;96(4):446-454. doi: 10.1002/ajh.26092. Epub 2021 Jan 28. Am J Hematol. 2021. PMID: 33428787 Free article.
979 results